Pharmacokinetic investigations of isavuconazole in paediatric cancer patients show reduced exposure of isavuconazole after opening capsules for administration via a nasogastric tube

  • Didi Bury*
  • , Tom F.W. Wolfs
  • , Rob ter Heine
  • , Eline W. Muilwijk
  • , Kim C.M. van der Elst
  • , Wim J.E. Tissing
  • , Roger J.M. Brüggemann
  • *Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    3 Citations (Scopus)
    207 Downloads (Pure)

    Abstract

    Objectives: To study the isavuconazole pharmacokinetics in a real-life paediatric cohort and confirm whether the isavuconazole exposures are within the adult exposure range. Furthermore, we are the first to describe unbound isavuconazole pharmacokinetics. 

    Methods: In this prospective, observational study, the isavuconazole dosing regimen was as follows (IV/oral/ nasogastric tube): 5.4 mg/kg isavuconazole (maximum 200 mg/dose) three times daily on Days 1 and 2, followed by 5.4 mg/kg isavuconazole (maximum 200 mg/dose) once daily. At least one pharmacokinetic curve was assessed. Non-linear mixed effects modelling was used for analysis. Monte Carlo simulations were performed with the above mentioned maintenance dose for IV administrations and a weight band dosing regimen for oral/nasogastric tube administrations: I) <18 kg (100 mg daily); II) 18–37 kg (150 mg daily); III) >37 kg (200 mg daily). 

    Results: Seventeen paediatric patients with a median age of 9 years (range 1–17) and median weight of 26.0 kg (range 8.4–78.5) were evaluated. A two-compartment model describing linear pharmacokinetics of the unbound concentrations and saturable protein binding fitted the isavuconazole concentrations best. The absolute bioavailability of isavuconazole was 41.0% (95% CI: 32.4%–50.8%). The median (IQR) simulated exposures (AUC0–24h, SS) of the total isavuconazole concentrations after IV and oral/nasogastric tube administration were 87.7 mg·h/L (70.5–105.1) and 50.3 mg·h/L (39.0–62.4), respectively. The unbound isavuconazole fraction (unbound/total) ranged from 0.5% to 2.3%. 

    Conclusions: This study revealed low bioavailability after nasogastric tube administration with opened capsules. Isavuconazole exposures were in the expected range following IV administration. Total and unbound isavuconazole pharmacokinetics were reported with a 5-fold range in the unbound fraction.

    Original languageEnglish
    Pages (from-to)2886-2889
    Number of pages4
    JournalJournal of Antimicrobial Chemotherapy
    Volume78
    Issue number12
    DOIs
    Publication statusPublished - Dec-2023

    Keywords

    • biological availability
    • adult
    • pediatrics
    • pharmacokinetics
    • childhood cancer
    • nasogastric tube
    • isavuconazole

    Fingerprint

    Dive into the research topics of 'Pharmacokinetic investigations of isavuconazole in paediatric cancer patients show reduced exposure of isavuconazole after opening capsules for administration via a nasogastric tube'. Together they form a unique fingerprint.

    Cite this